BioCentury
ARTICLE | Clinical News

SF0166 Topical Ophthalmic Solution: Phase I/II started

October 24, 2016 7:00 AM UTC

SciFluor began a double-blind, U.S. Phase I/II trial to evaluate 2 dose levels of twice-daily SF0166 Topical Ophthalmic Solution for 28 days in up to 40 patients....